{
  "DOI": "10.1038/ejhg.2016.93",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/ejhg.2016.93",
  "alternative-id": [
    "BFejhg201693"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 1,
      "value": "12 August 2016"
    },
    {
      "group": {
        "label": "Competing interests",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1,
      "value": "Dominique Stoppa-Lyonnet has received payments for speaker services from AstraZeneca. Her laboratory is supported by public funds from the French National Cancer Institute and AstraZeneca France, Inserm-Transfert."
    }
  ],
  "author": [
    {
      "affiliation": [],
      "family": "Stoppa-Lyonnet",
      "given": "Dominique",
      "sequence": "first"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ],
    "date-time": "2016-08-12T08:50:59Z",
    "timestamp": 1470991859000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        18
      ]
    ],
    "date-time": "2023-05-18T17:17:56Z",
    "timestamp": 1684430276000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        4,
        24
      ]
    ],
    "date-time": "2024-04-24T08:33:06Z",
    "timestamp": 1713947586469
  },
  "is-referenced-by-count": 61,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "S1",
  "issued": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ]
  },
  "journal-issue": {
    "issue": "S1",
    "published-print": {
      "date-parts": [
        [
          2016,
          9
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by-nc-sa/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2016,
            8,
            12
          ]
        ],
        "date-time": "2016-08-12T00:00:00Z",
        "timestamp": 1470960000000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/ejhg201693.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/ejhg201693",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/ejhg201693.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "S3-S9",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2016,
        8,
        12
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2016,
        9
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1126/science.2270482",
      "author": "JM Hall",
      "doi-asserted-by": "crossref",
      "first-page": "1684",
      "journal-title": "Science",
      "key": "BFejhg201693_CR1",
      "unstructured": "Hall JM, Lee MK, Newman B et al: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250: 1684–1689.",
      "volume": "250",
      "year": "1990"
    },
    {
      "DOI": "10.1126/science.7545954",
      "author": "Y Miki",
      "doi-asserted-by": "publisher",
      "first-page": "66",
      "journal-title": "Science",
      "key": "BFejhg201693_CR2",
      "unstructured": "Miki Y, Swensen J, Shattuck-Eidens D et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.",
      "volume": "266",
      "year": "1994"
    },
    {
      "DOI": "10.1038/ng0396-333",
      "author": "SV Tavtigian",
      "doi-asserted-by": "crossref",
      "first-page": "333",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR3",
      "unstructured": "Tavtigian SV, Simard J, Rommens J et al: The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333–337.",
      "volume": "12",
      "year": "1996"
    },
    {
      "DOI": "10.1126/science.8091231",
      "author": "R Wooster",
      "doi-asserted-by": "crossref",
      "first-page": "2088",
      "journal-title": "Science",
      "key": "BFejhg201693_CR4",
      "unstructured": "Wooster R, Neuhausen SL, Mangion J et al: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265: 2088–2090.",
      "volume": "265",
      "year": "1994"
    },
    {
      "DOI": "10.1038/sj.onc.1209874",
      "author": "K Gudmundsdottir",
      "doi-asserted-by": "crossref",
      "first-page": "5864",
      "journal-title": "Oncogene",
      "key": "BFejhg201693_CR5",
      "unstructured": "Gudmundsdottir K, Ashworth A : The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864–5874.",
      "volume": "25",
      "year": "2006"
    },
    {
      "DOI": "10.1242/jcs.114.20.3591",
      "author": "AR Venkitaraman",
      "doi-asserted-by": "crossref",
      "first-page": "3591",
      "journal-title": "J Cell Sci",
      "key": "BFejhg201693_CR6",
      "unstructured": "Venkitaraman AR : Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114: 3591–3598.",
      "volume": "114",
      "year": "2001"
    },
    {
      "DOI": "10.1200/JCO.2006.09.1066",
      "author": "S Chen",
      "doi-asserted-by": "crossref",
      "first-page": "1329",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201693_CR7",
      "unstructured": "Chen S, Parmigiani G : Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329–1333.",
      "volume": "25",
      "year": "2007"
    },
    {
      "DOI": "10.1093/jnci/djt095",
      "author": "N Mavaddat",
      "doi-asserted-by": "crossref",
      "first-page": "812",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg201693_CR8",
      "unstructured": "Mavaddat N, Peock S, Frost D et al: Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013; 105: 812–822.",
      "volume": "105",
      "year": "2013"
    },
    {
      "author": "N Collins",
      "first-page": "1673",
      "journal-title": "Oncogene",
      "key": "BFejhg201693_CR9",
      "unstructured": "Collins N, McManus R, Wooster R et al: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995; 10: 1673–1675.",
      "volume": "10",
      "year": "1995"
    },
    {
      "DOI": "10.1038/ng1092-128",
      "author": "SA Smith",
      "doi-asserted-by": "crossref",
      "first-page": "128",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR10",
      "unstructured": "Smith SA, Easton DF, Evans DG, Ponder BA : Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet 1992; 2: 128–131.",
      "volume": "2",
      "year": "1992"
    },
    {
      "DOI": "10.1093/hmg/10.26.3001",
      "author": "M Esteller",
      "doi-asserted-by": "crossref",
      "first-page": "3001",
      "journal-title": "Hum Mol Genet",
      "key": "BFejhg201693_CR11",
      "unstructured": "Esteller M, Fraga MF, Guo M et al: DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10: 3001–3007.",
      "volume": "10",
      "year": "2001"
    },
    {
      "author": "M Burgess",
      "first-page": "19",
      "journal-title": "Front Oncol",
      "key": "BFejhg201693_CR12",
      "unstructured": "Burgess M, Puhalla S : BRCA 1/2-mutation related and sporadic breast and ovarian cancers: more alike than different. Front Oncol 2014; 4: 19.",
      "volume": "4",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2011.39.8545",
      "author": "K Alsop",
      "doi-asserted-by": "crossref",
      "first-page": "2654",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201693_CR13",
      "unstructured": "Alsop K, Fereday S, Meldrum C et al: BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30: 2654–2663.",
      "volume": "30",
      "year": "2012"
    },
    {
      "author": "JM Lee",
      "first-page": "dju089",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg201693_CR14",
      "unstructured": "Lee JM, Hays JL, Annunziata CM et al: Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses. J Natl Cancer Inst 2014; 106: dju089.",
      "volume": "106",
      "year": "2014"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-13-2287",
      "author": "KP Pennington",
      "doi-asserted-by": "crossref",
      "first-page": "764",
      "journal-title": "Clin Cancer Res",
      "key": "BFejhg201693_CR15",
      "unstructured": "Pennington KP, Walsh T, Harrell MI et al: Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014; 20: 764–775.",
      "volume": "20",
      "year": "2014"
    },
    {
      "DOI": "10.4161/cc.7.18.6679",
      "author": "Z Mao",
      "doi-asserted-by": "crossref",
      "first-page": "2902",
      "journal-title": "Cell Cycle",
      "key": "BFejhg201693_CR16",
      "unstructured": "Mao Z, Bozzella M, Seluanov A, Gorbunova V : DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 2008; 7: 2902–2906.",
      "volume": "7",
      "year": "2008"
    },
    {
      "DOI": "10.1101/sqb.2005.70.012",
      "author": "AN Tutt",
      "doi-asserted-by": "crossref",
      "first-page": "139",
      "journal-title": "Cold Spring Harb Symp Quant Biol",
      "key": "BFejhg201693_CR17",
      "unstructured": "Tutt AN, Lord CJ, McCabe N et al: Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol 2005; 70: 139–148.",
      "volume": "70",
      "year": "2005"
    },
    {
      "DOI": "10.1016/S0092-8674(02)00615-3",
      "author": "AR Venkitaraman",
      "doi-asserted-by": "crossref",
      "first-page": "171",
      "journal-title": "Cell",
      "key": "BFejhg201693_CR18",
      "unstructured": "Venkitaraman AR : Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171–182.",
      "volume": "108",
      "year": "2002"
    },
    {
      "DOI": "10.1016/S0092-8674(00)81847-4",
      "author": "R Scully",
      "doi-asserted-by": "crossref",
      "first-page": "265",
      "journal-title": "Cell",
      "key": "BFejhg201693_CR19",
      "unstructured": "Scully R, Chen J, Plug A et al: Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 1997; 88: 265–275.",
      "volume": "88",
      "year": "1997"
    },
    {
      "DOI": "10.1126/science.1073834",
      "author": "NG Howlett",
      "doi-asserted-by": "crossref",
      "first-page": "606",
      "journal-title": "Science",
      "key": "BFejhg201693_CR20",
      "unstructured": "Howlett NG, Taniguchi T, Olson S et al: Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606–609.",
      "volume": "297",
      "year": "2002"
    },
    {
      "DOI": "10.1016/S1097-2765(00)80035-0",
      "author": "KJ Patel",
      "doi-asserted-by": "crossref",
      "first-page": "347",
      "journal-title": "Mol Cell",
      "key": "BFejhg201693_CR21",
      "unstructured": "Patel KJ, Yu VP, Lee H et al: Involvement of Brca2 in DNA repair. Mol Cell 1998; 1: 347–357.",
      "volume": "1",
      "year": "1998"
    },
    {
      "DOI": "10.1038/ng0207-142",
      "author": "KJ Patel",
      "doi-asserted-by": "crossref",
      "first-page": "142",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR22",
      "unstructured": "Patel KJ : Fanconi anemia and breast cancer susceptibility. Nat Genet 2007; 39: 142–143.",
      "volume": "39",
      "year": "2007"
    },
    {
      "DOI": "10.1016/j.molcel.2012.07.029",
      "author": "JR Chapman",
      "doi-asserted-by": "crossref",
      "first-page": "497",
      "journal-title": "Mol Cell",
      "key": "BFejhg201693_CR23",
      "unstructured": "Chapman JR, Taylor MR, Boulton SJ : Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 2012; 47: 497–510.",
      "volume": "47",
      "year": "2012"
    },
    {
      "author": "RB Jensen",
      "first-page": "479",
      "journal-title": "Yale J Biol Med",
      "key": "BFejhg201693_CR24",
      "unstructured": "Jensen RB : BRCA2: one small step for DNA repair, one giant protein purified. Yale J Biol Med 2013; 86: 479–489.",
      "volume": "86",
      "year": "2013"
    },
    {
      "DOI": "10.1038/nature10166",
      "author": "Cancer Genome Atlas Research Network",
      "doi-asserted-by": "crossref",
      "first-page": "609",
      "journal-title": "Nature",
      "key": "BFejhg201693_CR25",
      "unstructured": "Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615.",
      "volume": "474",
      "year": "2011"
    },
    {
      "DOI": "10.1073/pnas.0811159106",
      "author": "SM Sy",
      "doi-asserted-by": "crossref",
      "first-page": "7155",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "BFejhg201693_CR26",
      "unstructured": "Sy SM, Huen MS, Chen J : PALB2 is an integral component of the BRCA complex required for homologous recombination repair. Proc Natl Acad Sci USA 2009; 106: 7155–7160.",
      "volume": "106",
      "year": "2009"
    },
    {
      "DOI": "10.1038/nrc1457",
      "author": "N Turner",
      "doi-asserted-by": "crossref",
      "first-page": "814",
      "journal-title": "Nat Rev Cancer",
      "key": "BFejhg201693_CR27",
      "unstructured": "Turner N, Tutt A, Ashworth A : Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4: 814–819.",
      "volume": "4",
      "year": "2004"
    },
    {
      "DOI": "10.1056/NEJMoa1400382",
      "author": "AC Antoniou",
      "doi-asserted-by": "crossref",
      "first-page": "497",
      "journal-title": "N Engl J Med",
      "key": "BFejhg201693_CR28",
      "unstructured": "Antoniou AC, Casadei S, Heikkinen T et al: Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014; 371: 497–506.",
      "volume": "371",
      "year": "2014"
    },
    {
      "DOI": "10.1200/JCO.2014.57.1414",
      "author": "FJ Couch",
      "doi-asserted-by": "crossref",
      "first-page": "304",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201693_CR29",
      "unstructured": "Couch FJ, Hart SN, Sharma P et al: Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol 2015; 33: 304–311.",
      "volume": "33",
      "year": "2015"
    },
    {
      "DOI": "10.1038/ng1959",
      "author": "N Rahman",
      "doi-asserted-by": "crossref",
      "first-page": "165",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR30",
      "unstructured": "Rahman N, Seal S, Thompson D et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet 2007; 39: 165–167.",
      "volume": "39",
      "year": "2007"
    },
    {
      "DOI": "10.1038/ng1837",
      "author": "A Renwick",
      "doi-asserted-by": "crossref",
      "first-page": "873",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR31",
      "unstructured": "Renwick A, Thompson D, Seal S et al: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006; 38: 873–875.",
      "volume": "38",
      "year": "2006"
    },
    {
      "DOI": "10.1038/ng1902",
      "author": "S Seal",
      "doi-asserted-by": "crossref",
      "first-page": "1239",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR32",
      "unstructured": "Seal S, Thompson D, Renwick A et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet 2006; 38: 1239–1241.",
      "volume": "38",
      "year": "2006"
    },
    {
      "DOI": "10.1038/ng1625",
      "author": "M Levitus",
      "doi-asserted-by": "crossref",
      "first-page": "934",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR33",
      "unstructured": "Levitus M, Waisfisz Q, Godthelp BC et al: The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet 2005; 37: 934–935.",
      "volume": "37",
      "year": "2005"
    },
    {
      "DOI": "10.1038/ng1947",
      "author": "S Reid",
      "doi-asserted-by": "crossref",
      "first-page": "162",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR34",
      "unstructured": "Reid S, Schindler D, Hanenberg H et al: Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 2007; 39: 162–164.",
      "volume": "39",
      "year": "2007"
    },
    {
      "DOI": "10.1038/ncomms4156",
      "author": "KL Kanchi",
      "doi-asserted-by": "crossref",
      "first-page": "3156",
      "journal-title": "Nat Commun",
      "key": "BFejhg201693_CR35",
      "unstructured": "Kanchi KL, Johnson KJ, Lu C et al: Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun 2014; 5: 3156.",
      "volume": "5",
      "year": "2014"
    },
    {
      "DOI": "10.1093/jnci/djv214",
      "doi-asserted-by": "crossref",
      "key": "BFejhg201693_CR36",
      "unstructured": "Ramus SJ, Song H, Dicks E, Tyrer JP, Rosenthal AN, Intermaggio MP et al: Germline disease-causing variants in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J Natl Cancer Inst 2015, e-pub ahead of print 27 August 2015 doi:10.1093/jnci/djv214."
    },
    {
      "DOI": "10.4238/2013.November.22.6",
      "author": "LP Ren",
      "doi-asserted-by": "crossref",
      "first-page": "5793",
      "journal-title": "Genet Mol Res",
      "key": "BFejhg201693_CR37",
      "unstructured": "Ren LP, Xian YS, Diao DM, Chen Y, Guo Q, Dang CX : Further evidence for the contribution of the BRCA1-interacting protein-terminal helicase 1 (BRIP1) gene in breast cancer susceptibility. Genet Mol Res 2013; 12: 5793–5801.",
      "volume": "12",
      "year": "2013"
    },
    {
      "DOI": "10.1126/science.7792600",
      "author": "K Savitsky",
      "doi-asserted-by": "crossref",
      "first-page": "1749",
      "journal-title": "Science",
      "key": "BFejhg201693_CR38",
      "unstructured": "Savitsky K, Bar-Shira A, Gilad S et al: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268: 1749–1753.",
      "volume": "268",
      "year": "1995"
    },
    {
      "DOI": "10.1038/nrc799",
      "author": "T Skorski",
      "doi-asserted-by": "crossref",
      "first-page": "351",
      "journal-title": "Nat Rev Cancer",
      "key": "BFejhg201693_CR39",
      "unstructured": "Skorski T : Oncogenic tyrosine kinases and the DNA-damage response. Nat Rev Cancer 2002; 2: 351–360.",
      "volume": "2",
      "year": "2002"
    },
    {
      "DOI": "10.1038/srep04026",
      "author": "JM Cunningham",
      "doi-asserted-by": "crossref",
      "first-page": "4026",
      "journal-title": "Sci Rep",
      "key": "BFejhg201693_CR40",
      "unstructured": "Cunningham JM, Cicek MS, Larson NB et al: Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep 2014; 4: 4026.",
      "volume": "4",
      "year": "2014"
    },
    {
      "DOI": "10.1038/ng.569",
      "author": "A Meindl",
      "doi-asserted-by": "crossref",
      "first-page": "410",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR41",
      "unstructured": "Meindl A, Hellebrand H, Wiek C et al: Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010; 42: 410–414.",
      "volume": "42",
      "year": "2010"
    },
    {
      "DOI": "10.1097/PPO.0b013e31826246c2",
      "author": "SM Weissman",
      "doi-asserted-by": "crossref",
      "first-page": "320",
      "journal-title": "Cancer J",
      "key": "BFejhg201693_CR42",
      "unstructured": "Weissman SM, Weiss SM, Newlin AC : Genetic testing by cancer site: ovary. Cancer J 2012; 18: 320–327.",
      "volume": "18",
      "year": "2012"
    },
    {
      "DOI": "10.1111/cge.12548",
      "author": "V Sopik",
      "doi-asserted-by": "crossref",
      "first-page": "303",
      "journal-title": "Clin Genet",
      "key": "BFejhg201693_CR43",
      "unstructured": "Sopik V, Akbari MR, Narod SA. : Genetic testing for RAD51C mutations: in the clinic and community. Clin Genet 2015; 88: 303–312.",
      "volume": "88",
      "year": "2015"
    },
    {
      "DOI": "10.1186/1471-2407-13-484",
      "author": "L Golmard",
      "doi-asserted-by": "crossref",
      "first-page": "484",
      "journal-title": "BMC Cancer",
      "key": "BFejhg201693_CR44",
      "unstructured": "Golmard L, Caux-Moncoutier V, Davy G et al: Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer 2013; 13: 484.",
      "volume": "13",
      "year": "2013"
    },
    {
      "DOI": "10.1111/cge.12256",
      "author": "FS Hilbers",
      "doi-asserted-by": "crossref",
      "first-page": "407",
      "journal-title": "Clin Genet",
      "key": "BFejhg201693_CR45",
      "unstructured": "Hilbers FS, Vreeswijk MP, van Asperen CJ, Devilee P : The impact of next generation sequencing on the analysis of breast cancer susceptibility: a role for extremely rare genetic variation? Clin Genet 2013; 84: 407–414.",
      "volume": "84",
      "year": "2013"
    },
    {
      "DOI": "10.1038/ng.893",
      "author": "C Loveday",
      "doi-asserted-by": "crossref",
      "first-page": "879",
      "journal-title": "Nat Genet",
      "key": "BFejhg201693_CR46",
      "unstructured": "Loveday C, Turnbull C, Ramsay E et al: Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet 2011; 43: 879–882.",
      "volume": "43",
      "year": "2011"
    },
    {
      "DOI": "10.1007/s12032-014-0300-5",
      "author": "MM Michalska",
      "doi-asserted-by": "crossref",
      "first-page": "300",
      "journal-title": "Med Oncol",
      "key": "BFejhg201693_CR47",
      "unstructured": "Michalska MM, Samulak D, Smolarz B : An association between the -41657 C/T polymorphism of X-ray repair cross-complementing 2 (XRCC2) gene and ovarian cancer. Med Oncol 2014; 31: 300.",
      "volume": "31",
      "year": "2014"
    },
    {
      "DOI": "10.1016/j.ajhg.2012.02.027",
      "author": "DJ Park",
      "doi-asserted-by": "crossref",
      "first-page": "734",
      "journal-title": "Am J Hum Genet",
      "key": "BFejhg201693_CR48",
      "unstructured": "Park DJ, Lesueur F, Nguyen-Dumont T et al: Rare mutations in XRCC2 increase the risk of breast cancer. Am J Hum Genet 2012; 90: 734–739.",
      "volume": "90",
      "year": "2012"
    },
    {
      "author": "SA Martin",
      "first-page": "281",
      "journal-title": "J Pathol",
      "key": "BFejhg201693_CR49",
      "unstructured": "Martin SA, Hewish M, Lord CJ, Ashworth A : Genomic instability and the selection of treatments for cancer. J Pathol 2010; 220: 281–289.",
      "volume": "220",
      "year": "2010"
    },
    {
      "DOI": "10.1038/nature03443",
      "author": "HE Bryant",
      "doi-asserted-by": "crossref",
      "first-page": "913",
      "journal-title": "Nature",
      "key": "BFejhg201693_CR50",
      "unstructured": "Bryant HE, Schultz N, Thomas HD et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434: 913–917.",
      "volume": "434",
      "year": "2005"
    },
    {
      "DOI": "10.1038/nature03445",
      "author": "H Farmer",
      "doi-asserted-by": "crossref",
      "first-page": "917",
      "journal-title": "Nature",
      "key": "BFejhg201693_CR51",
      "unstructured": "Farmer H, McCabe N, Lord CJ et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917–921.",
      "volume": "434",
      "year": "2005"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-06-0140",
      "author": "N McCabe",
      "doi-asserted-by": "crossref",
      "first-page": "8109",
      "journal-title": "Cancer Res",
      "key": "BFejhg201693_CR52",
      "unstructured": "McCabe N, Turner NC, Lord CJ et al: Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109–8115.",
      "volume": "66",
      "year": "2006"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-07-4953",
      "author": "B Evers",
      "doi-asserted-by": "crossref",
      "first-page": "3916",
      "journal-title": "Clin Cancer Res",
      "key": "BFejhg201693_CR53",
      "unstructured": "Evers B, Drost R, Schut E et al: Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008; 14: 3916–3925.",
      "volume": "14",
      "year": "2008"
    },
    {
      "DOI": "10.1073/pnas.0806092105",
      "author": "S Rottenberg",
      "doi-asserted-by": "publisher",
      "first-page": "17079",
      "journal-title": "Proc Natl Acad Sci USA",
      "key": "BFejhg201693_CR54",
      "unstructured": "Rottenberg S, Jaspers JE, Kersbergen A et al: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 2008; 105: 17079–17084.",
      "volume": "105",
      "year": "2008"
    },
    {
      "DOI": "10.1016/S0140-6736(10)60893-8",
      "author": "MW Audeh",
      "doi-asserted-by": "crossref",
      "first-page": "245",
      "journal-title": "Lancet",
      "key": "BFejhg201693_CR55",
      "unstructured": "Audeh MW, Carmichael J, Penson RT et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–251.",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1016/S0140-6736(10)60892-6",
      "author": "A Tutt",
      "doi-asserted-by": "crossref",
      "first-page": "235",
      "journal-title": "Lancet",
      "key": "BFejhg201693_CR56",
      "unstructured": "Tutt A, Robson M, Garber JE et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235–244.",
      "volume": "376",
      "year": "2010"
    },
    {
      "DOI": "10.1016/S1470-2045(14)70228-1",
      "author": "J Ledermann",
      "doi-asserted-by": "crossref",
      "first-page": "852",
      "journal-title": "Lancet Oncol",
      "key": "BFejhg201693_CR57",
      "unstructured": "Ledermann J, Harter P, Gourley C et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–861.",
      "volume": "15",
      "year": "2014"
    },
    {
      "DOI": "10.1086/375033",
      "author": "A Antoniou",
      "doi-asserted-by": "crossref",
      "first-page": "1117",
      "journal-title": "Am J Hum Genet",
      "key": "BFejhg201693_CR58",
      "unstructured": "Antoniou A, Pharoah PD, Narod S et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130.",
      "volume": "72",
      "year": "2003"
    },
    {
      "DOI": "10.1111/cge.12505",
      "author": "J Abugattas",
      "doi-asserted-by": "crossref",
      "first-page": "371",
      "journal-title": "Clin Genet",
      "key": "BFejhg201693_CR59",
      "unstructured": "Abugattas J, Llacuachaqui M, Allende YS et al: Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet 2014; 88: 371–375.",
      "volume": "88",
      "year": "2014"
    },
    {
      "DOI": "10.3346/jkms.2004.19.2.269",
      "author": "SH Ahn",
      "doi-asserted-by": "crossref",
      "first-page": "269",
      "journal-title": "J Korean Med Sci",
      "key": "BFejhg201693_CR60",
      "unstructured": "Ahn SH, Hwang UK, Kwak BS et al: Prevalence of BRCA1 and BRCA2 mutations in Korean breast cancer patients. J Korean Med Sci 2004; 19: 269–274.",
      "volume": "19",
      "year": "2004"
    },
    {
      "DOI": "10.1016/j.ygyno.2007.09.035",
      "author": "I Brozek",
      "doi-asserted-by": "crossref",
      "first-page": "433",
      "journal-title": "Gynecol Oncol",
      "key": "BFejhg201693_CR61",
      "unstructured": "Brozek I, Ochman K, Debniak J et al: High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland. Gynecol Oncol 2008; 108: 433–437.",
      "volume": "108",
      "year": "2008"
    },
    {
      "DOI": "10.1002/ijc.10194",
      "author": "ML De Leon Matsuda",
      "doi-asserted-by": "crossref",
      "first-page": "596",
      "journal-title": "Int J Cancer",
      "key": "BFejhg201693_CR62",
      "unstructured": "De Leon Matsuda ML, Liede A, Kwan E et al: BRCA1 and BRCA2 mutations among breast cancer patients from the Philippines. Int J Cancer 2002; 98: 596–603.",
      "volume": "98",
      "year": "2002"
    },
    {
      "DOI": "10.1111/j.1399-0004.2010.01545.x",
      "author": "OM Ginsburg",
      "doi-asserted-by": "crossref",
      "first-page": "89",
      "journal-title": "Clin Genet",
      "key": "BFejhg201693_CR63",
      "unstructured": "Ginsburg OM, Dinh NV, To TV et al: Family history, BRCA mutations and breast cancer in Vietnamese women. Clin Genet 2011; 80: 89–92.",
      "volume": "80",
      "year": "2011"
    },
    {
      "DOI": "10.1186/1897-4287-12-11",
      "author": "JE Hernández",
      "doi-asserted-by": "crossref",
      "first-page": "11",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "BFejhg201693_CR64",
      "unstructured": "Hernández JE, Llacuachaqui M, Palacio GV et al: Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellin, Colombia. Hered Cancer Clin Pract 2014; 12: 11.",
      "volume": "12",
      "year": "2014"
    },
    {
      "DOI": "10.1097/GIM.0b013e318032e4ab",
      "author": "CE Jacobi",
      "doi-asserted-by": "crossref",
      "first-page": "173",
      "journal-title": "Genet Med",
      "key": "BFejhg201693_CR65",
      "unstructured": "Jacobi CE, van Ierland Y, van Asperen CJ et al: Prediction of BRCA1/2 mutation status in patients with ovarian cancer from a hospital-based cohort. Genet Med 2007; 9: 173–179.",
      "volume": "9",
      "year": "2007"
    },
    {
      "DOI": "10.1186/1897-4287-9-10",
      "author": "C Koumpis",
      "doi-asserted-by": "crossref",
      "first-page": "10",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "BFejhg201693_CR66",
      "unstructured": "Koumpis C, Dimitrakakis C, Antsaklis A et al: Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Greece. Hered Cancer Clin Pract 2011; 9: 10.",
      "volume": "9",
      "year": "2011"
    },
    {
      "author": "A Laudico",
      "first-page": "167",
      "journal-title": "Asian Pac J Cancer Prev",
      "key": "BFejhg201693_CR67",
      "unstructured": "Laudico A, Redaniel MT, Mirasol-Lumague MR et al: Epidemiology and clinicopathology of breast cancer in metro Manila and Rizal Province, Philippines. Asian Pac J Cancer Prev 2009; 10: 167–172.",
      "volume": "10",
      "year": "2009"
    },
    {
      "DOI": "10.1016/j.ejca.2003.09.016",
      "author": "S Malander",
      "doi-asserted-by": "crossref",
      "first-page": "422",
      "journal-title": "Eur J Cancer",
      "key": "BFejhg201693_CR68",
      "unstructured": "Malander S, Ridderheim M, Masback A et al: One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. Eur J Cancer 2004; 40: 422–428.",
      "volume": "40",
      "year": "2004"
    },
    {
      "DOI": "10.1002/ijc.11338",
      "author": "J Menkiszak",
      "doi-asserted-by": "crossref",
      "first-page": "942",
      "journal-title": "Int J Cancer",
      "key": "BFejhg201693_CR69",
      "unstructured": "Menkiszak J, Gronwald J, Gorski B et al: Hereditary ovarian cancer in Poland. Int J Cancer 2003; 106: 942–945.",
      "volume": "106",
      "year": "2003"
    },
    {
      "DOI": "10.1086/318787",
      "author": "HA Risch",
      "doi-asserted-by": "crossref",
      "first-page": "700",
      "journal-title": "Am J Hum Genet",
      "key": "BFejhg201693_CR70",
      "unstructured": "Risch HA, McLaughlin JR, Cole DE et al: Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700–710.",
      "volume": "68",
      "year": "2001"
    },
    {
      "DOI": "10.1093/jnci/djj465",
      "author": "HA Risch",
      "doi-asserted-by": "crossref",
      "first-page": "1694",
      "journal-title": "J Natl Cancer Inst",
      "key": "BFejhg201693_CR71",
      "unstructured": "Risch HA, McLaughlin JR, Cole DE et al: Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006; 98: 1694–1706.",
      "volume": "98",
      "year": "2006"
    },
    {
      "DOI": "10.1016/j.ygyno.2011.10.027",
      "author": "AO Rodríguez",
      "doi-asserted-by": "crossref",
      "first-page": "236",
      "journal-title": "Gynecol Oncol",
      "key": "BFejhg201693_CR72",
      "unstructured": "Rodríguez AO, Llacuachaqui M, Pardo GG et al: BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol 2012; 124: 236–243.",
      "volume": "124",
      "year": "2012"
    },
    {
      "DOI": "10.1158/1078-0432.CCR-07-4806",
      "author": "M Soegaard",
      "doi-asserted-by": "crossref",
      "first-page": "3761",
      "journal-title": "Clin Cancer Res",
      "key": "BFejhg201693_CR73",
      "unstructured": "Soegaard M, Kjaer SK, Cox M et al: BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. Clin Cancer Res 2008; 14: 3761–3767.",
      "volume": "14",
      "year": "2008"
    },
    {
      "DOI": "10.1093/annonc/mdr373",
      "author": "J Balmaña",
      "doi-asserted-by": "crossref",
      "first-page": "vi31",
      "issue": "Suppl 6",
      "journal-title": "Ann Oncol",
      "key": "BFejhg201693_CR74",
      "unstructured": "Balmaña J, Diez O, Rubio IT, Cardoso F. : BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl 6): vi31–vi34.",
      "volume": "22",
      "year": "2011"
    },
    {
      "DOI": "10.1186/bcr1750",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "213",
      "journal-title": "Breast Cancer Res",
      "key": "BFejhg201693_CR75",
      "unstructured": "Evans DG, Howell A : Breast cancer risk-assessment models. Breast Cancer Res 2007; 9: 213.",
      "volume": "9",
      "year": "2007"
    },
    {
      "DOI": "10.1136/jmedgenet-2013-101674",
      "author": "B Bonaiti",
      "doi-asserted-by": "crossref",
      "first-page": "114",
      "journal-title": "J Med Genet",
      "key": "BFejhg201693_CR76",
      "unstructured": "Bonaiti B, Alarcon F, Andrieu N et al: A new scoring system in cancer genetics: application to criteria for BRCA1 and BRCA2 mutation screening. J Med Genet 2014; 51: 114–121.",
      "volume": "51",
      "year": "2014"
    },
    {
      "DOI": "10.1136/jmg.2003.017996",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "474",
      "journal-title": "J Med Genet",
      "key": "BFejhg201693_CR77",
      "unstructured": "Evans DG, Eccles DM, Rahman N et al: A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 2004; 41: 474–480.",
      "volume": "41",
      "year": "2004"
    },
    {
      "DOI": "10.1136/jmg.2005.031989",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "e39",
      "journal-title": "J Med Genet",
      "key": "BFejhg201693_CR78",
      "unstructured": "Evans DG, Lalloo F, Wallace A, Rahman N : Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet 2005; 42: e39.",
      "volume": "42",
      "year": "2005"
    },
    {
      "DOI": "10.1684/bdc.2011.1397",
      "author": "B Bonaiti",
      "doi-asserted-by": "crossref",
      "first-page": "779",
      "journal-title": "Bull Cancer",
      "key": "BFejhg201693_CR79",
      "unstructured": "Bonaiti B, Alarcon F, Bonadona V et al: [A new scoring system for the diagnosis of BRCA1/2 associated breast-ovarian cancer predisposition]. Bull Cancer 2011; 98: 779–795.",
      "volume": "98",
      "year": "2011"
    },
    {
      "DOI": "10.1200/JCO.2008.16.6231",
      "author": "DP Atchley",
      "doi-asserted-by": "crossref",
      "first-page": "4282",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201693_CR80",
      "unstructured": "Atchley DP, Albarracin CT, Lopez A et al: Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol 2008; 26: 4282–4288.",
      "volume": "26",
      "year": "2008"
    },
    {
      "DOI": "10.1136/jmg.2009.067850",
      "author": "DG Evans",
      "doi-asserted-by": "crossref",
      "first-page": "811",
      "journal-title": "J Med Genet",
      "key": "BFejhg201693_CR81",
      "unstructured": "Evans DG, Lalloo F, Cramer A et al: Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 2009; 46: 811–817.",
      "volume": "46",
      "year": "2009"
    },
    {
      "DOI": "10.1200/JCO.2006.06.5664",
      "author": "BG Haffty",
      "doi-asserted-by": "crossref",
      "first-page": "5652",
      "journal-title": "J Clin Oncol",
      "key": "BFejhg201693_CR82",
      "unstructured": "Haffty BG, Yang Q, Reiss M et al: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006; 24: 5652–5657.",
      "volume": "24",
      "year": "2006"
    },
    {
      "DOI": "10.1186/1471-2407-8-100",
      "author": "MM Litwiniuk",
      "doi-asserted-by": "crossref",
      "first-page": "100",
      "journal-title": "BMC Cancer",
      "key": "BFejhg201693_CR83",
      "unstructured": "Litwiniuk MM, Roznowski K, Filas V et al: Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. BMC Cancer 2008; 8: 100.",
      "volume": "8",
      "year": "2008"
    },
    {
      "DOI": "10.1038/bjc.2012.451",
      "author": "V Abkevich",
      "doi-asserted-by": "crossref",
      "first-page": "1776",
      "journal-title": "Br J Cancer",
      "key": "BFejhg201693_CR84",
      "unstructured": "Abkevich V, Timms KM, Hennessy BT et al: Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 2012; 107: 1776–1782.",
      "volume": "107",
      "year": "2012"
    },
    {
      "DOI": "10.1158/2159-8290.CD-11-0206",
      "author": "NJ Birkbak",
      "doi-asserted-by": "crossref",
      "first-page": "366",
      "journal-title": "Cancer Discov",
      "key": "BFejhg201693_CR85",
      "unstructured": "Birkbak NJ, Wang ZC, Kim JY et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov 2012; 2: 366–375.",
      "volume": "2",
      "year": "2012"
    },
    {
      "DOI": "10.1158/0008-5472.CAN-12-1470",
      "author": "T Popova",
      "doi-asserted-by": "crossref",
      "first-page": "5454",
      "journal-title": "Cancer Res",
      "key": "BFejhg201693_CR86",
      "unstructured": "Popova T, Manie E, Rieunier G et al: Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation. Cancer Res 2012; 72: 5454–5462.",
      "volume": "72",
      "year": "2012"
    },
    {
      "DOI": "10.1016/j.ygyno.2014.09.009",
      "author": "JM Lancaster",
      "doi-asserted-by": "crossref",
      "first-page": "3",
      "journal-title": "Gynecol Oncol",
      "key": "BFejhg201693_CR87",
      "unstructured": "Lancaster JM, Powell CB, Chen LM, Richardson DL : Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol 2015; 136: 3–7.",
      "volume": "136",
      "year": "2015"
    }
  ],
  "reference-count": 87,
  "references-count": 87,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/ejhg201693"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "The biological effects and clinical implications of BRCA mutations: where do we go from here?"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "24"
}